Suppr超能文献

成人强化型低级别胶质瘤的预后意义及文献综述

Prognostic significance of contrast-enhancing low-grade gliomas in adults and a review of the literature.

作者信息

Chaichana Kaisorn L, McGirt Matthew J, Niranjan Ashwini, Olivi Alessandro, Burger Peter C, Quinones-Hinojosa Alfredo

机构信息

Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.

出版信息

Neurol Res. 2009 Nov;31(9):931-9. doi: 10.1179/174313209X395454. Epub 2009 Feb 12.

Abstract

OBJECTIVES

Survival and tumor recurrence for patients with low-grade gliomas is heterogeneous, with reported survival and recurrence times varying by several months to years. The prognostic implications of a contrast-enhancing low-grade glioma remain less well understood.

METHODS

We retrospectively reviewed all adult patients who underwent a craniotomy for a hemispheric low-grade glioma (WHO grade II) from 1996 to 2006 at a single institution. Multivariate proportional hazards regression analysis was used to identify independent associations with survival, recurrence and malignant degeneration. Furthermore, a review of the literature for all works on low-grade gliomas and contrast enhancement was conducted.

RESULTS

One hundred eighty-nine patients (87 fibrillary astrocytomas, 89 oligodendrogliomas and 13 mixed gliomas) were available for analysis, with 64 (34%) and 125 (66%) contrast-enhancing and non-enhancing tumors, respectively. There were no significant differences in clinical and treatment-related variables between patients with and without contrast enhancement. After multivariate analysis, contrast enhancement was independently associated with decreased survival (p=0.006) and increased recurrence (p=0.04) and trended toward significance with malignant degeneration (p=0.15). Five-year overall survival, progression-free survival and malignancy-free survival rates for patients with enhancement versus patients without enhancement were 70 versus 85% (p=0.002), 32 versus 49% (p=0.008) and 74 versus 90% (p=0.002), respectively. The review of the literature identified 14 works that fit our criteria. The majority of these published works had design-related limitations including small population size as well as the inclusion of non-WHO grade II gliomas, pediatric patients and patient undergoing biopsy.

DISCUSSION

This study may provide insights into risk stratifying patients with low-grade gliomas and most specifically those that contrast enhance.

摘要

目的

低级别胶质瘤患者的生存率和肿瘤复发情况存在异质性,报告的生存和复发时间相差数月至数年。对比增强型低级别胶质瘤的预后意义仍了解较少。

方法

我们回顾性分析了1996年至2006年在单一机构接受半球低级别胶质瘤(世界卫生组织二级)开颅手术的所有成年患者。采用多变量比例风险回归分析来确定与生存、复发和恶性转化的独立关联。此外,还对所有关于低级别胶质瘤和对比增强的文献进行了综述。

结果

189例患者(87例纤维型星形细胞瘤、89例少突胶质细胞瘤和13例混合性胶质瘤)可供分析,其中分别有64例(34%)和125例(66%)为对比增强型和非增强型肿瘤。对比增强组和非增强组患者在临床和治疗相关变量方面无显著差异。多变量分析后,对比增强与生存率降低(p = 0.006)、复发增加(p = 0.04)独立相关,且与恶性转化有显著趋势(p = 0.15)。对比增强组和非增强组患者的5年总生存率、无进展生存率和无恶性变生存率分别为70%对85%(p = 0.002)、32%对49%(p = 0.008)和74%对90%(p = 0.002)。文献综述确定了14篇符合我们标准的研究。这些已发表研究中的大多数存在与设计相关的局限性,包括样本量小以及纳入了非世界卫生组织二级胶质瘤、儿科患者和接受活检的患者。

讨论

本研究可能为低级别胶质瘤患者,尤其是对比增强型患者的风险分层提供见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验